Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: February 18, 2025
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial.
Journal: Blood advances
Published: August 24, 2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Journal: The New England journal of medicine
Published: June 03, 2022
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Journal: Leukemia & lymphoma
Published: March 01, 2022
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
Journal: Leukemia
Published: November 05, 2021
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up.
Journal: HemaSphere
Published: November 04, 2021
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.
Journal: Cancer medicine
Published: December 22, 2020
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026